Shares of Catalent Inc (NASDAQ:CTLT) have been given an average recommendation of “Buy” by the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $32.00.
A number of equities analysts have weighed in on the stock. BidaskClub upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “buy” rating and set a $39.00 price target on the stock in a report on Tuesday, July 4th. William Blair upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Monday, May 15th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $37.00 price target (up previously from $32.00) on shares of Catalent in a report on Wednesday, May 17th.
Catalent (CTLT) traded up 2.05% during mid-day trading on Friday, hitting $34.89. The stock had a trading volume of 650,792 shares. The company has a market cap of $4.36 billion and a price-to-earnings ratio of 41.10. The company has a 50 day moving average price of $35.18 and a 200-day moving average price of $32.05. Catalent has a one year low of $21.83 and a one year high of $38.73.
In other news, SVP Christine Dolan sold 745 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total value of $25,963.25. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Several institutional investors have recently modified their holdings of the stock. Acrospire Investment Management LLC increased its position in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP increased its position in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares in the last quarter. Flinton Capital Management LLC increased its position in shares of Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares in the last quarter. Meadow Creek Investment Management LLC increased its position in shares of Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after buying an additional 559 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Catalent Inc (CTLT) Given Consensus Recommendation of “Buy” by Brokerages” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/18/catalent-inc-ctlt-given-consensus-recommendation-of-buy-by-brokerages.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.
